Press release
Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Acute Lymphoblastic Leukemia Disease Pipeline Drugs
Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc.
ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Trial Phase, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Novartis
• Pfizer
• Ariad Pharmaceuticals
• Juno Therapeutics
• Janssen
• Amgen
• (Erytech Pharma
• Bristol-Myers Squibb
• Others
By Drugs, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Blinatumomab
• Carfilzomib
• calaspargasepegol
• Dasatinib
• Ibrutinib
• Inotuzumabozogamicin
• Ofatumumab
• Ponatinib
• Others
By Route of Administration, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Oral
• Parenteral
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• In October 2015, Seattle Genetics, Inc.initiated randomized phase II clinical trial of denintuzumabmafodotin (SGN-CD19A) in combination with second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• In September 2017, Kiadis pharma’s ATR101 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by U.S.FDA and in April 2017, Kiadis pharma received regulatory approval from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201 for patients suffering from blood cancers
Report Description:
Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Lymphoblastic Leukemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Lymphoblastic Leukemia disease pipeline drugs development. This report studies the dynamics of the Acute Lymphoblastic Leukemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Lymphoblastic Leukemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1037064 • Views: …
More Releases from Precision Business Insights
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb…
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the…
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of…
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater…
More Releases for Acute
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
. .
Description-
' …
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.
Request For Sample Report…
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
